Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Activating mutations in the epidermal growth factor receptor (EGFR) gene are crucial drivers in non-small cell lung cancer (NSCLC).
• Targeted therapies inhibiting EGFR are a cornerstone in treating EGFR-mutation-positive advanced NSCLC.
• First-generation EGFR tyrosine kinase inhibitors (TKIs) have been standard, but resistance and limited central nervous system (CNS) penetration remain challenges.

Purpose of the Study:

• To evaluate the efficacy and safety of osimertinib, a third-generation EGFR-TKI, as a first-line treatment for advanced NSCLC with activating EGFR mutations.
• To compare osimertinib against first-generation EGFR-TKIs in terms of progression-free survival (PFS), overall survival (OS), and CNS efficacy.
• To assess the tolerability profile of osimertinib in this patient population.

Main Methods:

• The study was the pivotal phase III FLAURA trial, a randomized, double-blind, controlled study.
• Patients with previously untreated, EGFR mutation-positive, advanced NSCLC received either osimertinib or a first-generation EGFR-TKI.
• Key endpoints included PFS, OS, CNS PFS, and safety assessments.

Main Results:

• Osimertinib significantly prolonged both progression-free survival (PFS) and overall survival (OS) compared to first-generation EGFR-TKIs.
• Osimertinib demonstrated significant improvement in central nervous system (CNS) progression-free survival (PFS), particularly in patients with CNS metastases at baseline.
• The tolerability profile of osimertinib was manageable, with most treatment-related adverse events being mild to moderate in severity.

Conclusions:

• Osimertinib is a highly effective first-line treatment for patients with advanced NSCLC harboring activating EGFR mutations.
• Osimertinib offers significant survival benefits and superior CNS penetration compared to older EGFR-TKIs.
• Osimertinib presents a valuable and well-tolerated targeted therapeutic option for this patient group.